Evidence map›Paper›PMID 36895067›Full record

ArticlePerfusion2024

Is this dyspnea because of coronary artery disease? A rare case report of primary neuroendocrine tumor in anterior mediastinum.

Eglė Rumbinaitė, Rūta Dirsienė, Domas Vaitiekus, Lina Poškienė, Gabrielė Žūkaitė, Šarūnė Stankevičienė, Gintarė Šakalytė, Olivija Dobilienė, Rimantas Benetis

Open access · hybridAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Perfusion, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Eglė RumbinaitėAssociate Professor, Cardiologist, Department of Cardiology, Lithuanian University of Health Sciences, Kaunas, Lithuania.ORCID 0000-0003-2657-5745
Rūta DirsienėCardiologist, Department of Cardiology, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Domas VaitiekusDepartment of Oncology and Hematology, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Lina PoškienėDepartment of Pathology, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Gabrielė ŽūkaitėFaculty of Medicine, Lithuanian University of Health Sciences, Academy of Medicine, Druskininkai, Lithuania.
Šarūnė StankevičienėDepartment of Cardiology, Lithuanian University of Health Sciences, Kaunas, Lithuania.ORCID 0000-0001-9130-3709
Gintarė ŠakalytėCardiologist, Head of the Heart Failure and Defects Department, Department of Cardiology, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Olivija DobilienėCardiologist, Head of the Ischemic Heart Disease Department, Head of the Myocardial Infarction Sector of the Ischemic Heart Disease Department, Department of Cardiology, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Rimantas BenetisCardiac Surgeon, Head of the Cardiac, Thoracic and Vascular Surgery Clinic, Department of Cardiac, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Lithuanian University of Health Sciences · LT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMediastinal neuroendocrine tumors are rare malignancies with aggressive behavior and a grim prognosis. These malignancies often go undetected until they are diagnosed at advanced stages. CASE REPORT: We present the case of 74 -years old man who was hospitalized because of non-ST elevation myocardial infarction and in case of three vessels coronary artery disease, coronary bypass surgery was planned. During preoperative investigation, computer tomography revealed a huge tumor (20 cm × 11 cm × 21 cm in size) in the anterior mediastinum. Successful simultaneous operation coronary bypass surgery and removal of the mediastinal tumor was performed. DISCUSSION: Surgery is the treatment of choice for neuroendocrine tumors but the relapse rate ranges between 5% and 30% and is higher (65%) in atypical neuroendocrine tumors and patients with mediastinal node involvement. Despite the poor prognosis of neuroendocrine tumors, the spread to the lymph nodes, the patient continues chemotherapy treatment 49 months after the operation.

Indexed as

Coronary Artery DiseaseMediastinal NeoplasmsNeuroendocrine TumorsAgedDyspneaHumansMaleacute coronary syndromecarcinoid tumorchest paindyspneaneuroendocrine mediastinum tumor

Identifiers

PMID36895067
PMCPMC11083731
OpenAlexW4323807715

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.